Kelowna, British Columbia – May 23, 2019 – Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the “Company” or “Lexaria”), a drug delivery platform innovator, announces that on May 22, 2019 it issued the following securities: Incentive Stock Options, pursuant to…
Lexaria is technology for improved delivery of bioactive compounds.
CSE:LXX; OTCQX:LXRP
Welcome to Lexaria Bioscience Corp.
Lexaria Bioscience Corp. (CSE:LXX; OTCQX:LXRP) has developed and out-licenses its disruptive and cost-effective DehydraTECH™ technology that promotes healthier administration methods, lower overall dosing and higher effectiveness of ingestible drugs and other beneficial molecules.
Lexaria’s DehydraTECHTM delivery technology is protected by a robust suite of patents granted or pending worldwide and is proven effective in multiple international studies in greatly assisting rapidity and quantity of absorption of a range of lipophilic (i.e., fat-soluble), bioactive molecules. By significantly enhancing the performance and experience with oral ingestion, Lexaria’s DehydraTECH delivery technology offers a viable and often healthier alternative to other delivery methods for bioactive substances in widespread use today such as inhalational delivery through smoking.
About DehydraTECH
Lexaria’s patented technology, DehydraTECH™ delivers these important benefits:
Masks taste/odor
Eliminates the strong tastes/odors of lipophilic compounds, without the need for unwanted sugar or sweeteners
Reduces time of onset
Effects are felt within 15-20 min vs. 60-120 min.
Avoids first-pass liver metabolism
Initial testing indirectly evidences DehydraTECH may deliver ingested molecules through the lymphatic system instead of being subject to immediate “first pass” liver exposure, potentially mitigating unwanted side effects and reducing liver biotransformation.
Increases bio-absorption
Bio-absorption increases up to 3 – 10X, to equate or exceed that of other routes of administration like inhalational delivery.
Lexaria’s disruptive new technology DehydraTECH can be licensed to improve existing drug delivery through orally-ingested products; or create revolutionary new ones.
DehydraTECH Commercial Applications
Lexaria’s DehydraTECH™ is designed specifically for formulating and delivering lipophilic (i.e. fat-soluble) drug payloads. It is patented or patent-pending for use with a broad range of bioactive molecules, including but not limited to:
Latest News
Lexaria Bioscience and Nuka Enterprises’ 1906 Expand Cannabis Product Relationship
1906 fast-acting edibles products, powered by Lexaria’s DehydraTECH technology, will expand across the US in 2019 and 2020 Kelowna, British Columbia – Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX), an innovator in drug delivery platforms, today announced the most reliable fast…
Lexaria’s DehydraTECHTM Formulation Delivers 475% More CBD to Bloodstream after 15 Minutes than Conventional Industry Formulations
The DehydraTECH formulation delivered measurable quantities of cannabidiol (“CBD”) into blood in as little as 2 minutes; Lexaria’s technology delivered more CBD to bloodstream in 15 minutes than conventional medium chain triglyceride (“MCT”) oil based control formulation achieved in 60…